Healthcare News

  Market Overview:   A solid tumor can characterized by growth of abnormal mass or lump of tissues without liquid or cysts. It is classified into malignant tumor (cancerous) and the benign tumor (non-cancerous). Additionally, based on the cell type, tumors can be classified as sarcomas, carcinomas, and lymphomas. Competitive Landscape: Abbott Laboratories Inc., Biogen Idec Incorporated, AstraZeneca Plc., Johnson & Johnson Company, Amgen Inc., Bristol Myers Squibb Company, GlaxoSmithKline Plc., Sanofi, and Baxter International Incorporated Key Market Drivers: Growing popularity of biosimilars therapies is driving growth of the solid tumors treatment market . Moreover, rising prevalence of solid tumors is fueling market growth. According to the Centers for Disease Control and Prevention, in the United States in 2019, 1,752,735 new cancer cases were reported and 599,589 people died of cancer. For every 100,000 people, 439 new cancer cases were reported and 146 pe...

  Market Overview:   A solid tumor can characterized by growth of abnormal mass or lump of tissues without liquid or cysts. It is classified into malignant tumor (cancerous) and the benign tumor (non-cancerous). Additionally, based on the cell type, tumors can be classified as sarcomas, carcinomas, and lymphomas. Key Market Drivers: Growing popularity of biosimilars therapies is driving growth of the solidtumors treatment market . Moreover, rising prevalence of solid tumors is fueling market growth. According to the Centers for Disease Control and Prevention, in the United States in 2019, 1,752,735 new cancer cases were reported and 599,589 people died of cancer. For every 100,000 people, 439 new cancer cases were reported and 146 people died of cancer. Growing merger &acquisition in the market of cancer therapies by key players is again contributing to market growth. For instance, in July 2022, Takeda announced that it has acquire Adaptate Biotherapeutics to d...